SAB Biotherapeutics (SABS) Change in Acquisitions & Divestments (2024 - 2026)

SAB Biotherapeutics (SABS) has 3 years of Change in Acquisitions & Divestments data on file, last reported at $74.6 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 1473.26% year-over-year to $74.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.1 million (changed N/A YoY) and the FY2025 annual result came in at $21.3 million, down 17.66% from the prior year.
• Change in Acquisitions & Divestments advanced to $74.6 million in Q1 2026, from $11.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $74.6 million in Q1 2026 to a low of $3.8 million in Q3 2024.
• A 3-year average of $18.4 million and a median of $8.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments advanced 5.38% — and 2026, when it soared 1473.26%.
• Tracing SABS's Change in Acquisitions & Divestments over 3 years: stood at $10.7 million in 2024, then gained by 5.38% to $11.3 million in 2025, then soared by 561.86% to $74.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $74.6 million (Q1 2026), $11.3 million (Q4 2025), and $5.2 million (Q2 2025), per Business Quant data.